Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $45.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: Cencora, Cardinal Health, McKesson (76.0%); Concentration risk — Product: Qelbree (49.0%).
Supernus Pharmaceuticals is a commercial-stage CNS biopharmaceutical company with approved products for ADHD (Qelbree, ~49% of 2025 net revenues), Parkinson’s disease (GOCOVRI, ~23%), postpartum depression (ZURZUVAE, ~8%), epilepsy, and other conditions. Products are sold... Read more
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $45.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: Cencora, Cardinal Health, McKesson (76.0%); Concentration risk — Product: Qelbree (49.0%). Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Score 6.0/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-10Recent Developments — Supernus Pharmaceuticals, Inc.
Latest news
- NEWS A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance - simplywall.st — simplywall.st positive
- NEWS Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative positive
- NEWS SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative — Quiver Quantitative positive
- NEWS Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - StockStory — StockStory positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerCencora, Cardinal Health, McKesson76%10-K Item 1: 'Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of our total product revenue in 2025 and collectively accounted for more than 76%'
- HIGHProductQelbree49%10-K Item 1: 'Our major products Qelbree®, GOCOVRI®, Oxtellar XR®, APOKYN®, and ZURZUVAE® represented approximately 49%, 23%, 6%, and 8% of our total net revenues for the year ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-02-24Item 5.02LOWCompensation Committee approved modifications to executive officer compensation on February 18, 2026, including salary increases, 2025 bonuses, and equity grants for CEO Jack Khattar and other officers. Routine annual compensation cycle.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.5/10 is below the 5.0 floor at $45.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: Cencora, Cardinal Health, McKesson (76.0%); Concentration risk — Product: Qelbree (49.0%). Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Prior stop was $42.60. Score 6.0/10, moderate confidence.
Take-profit target: $54.66 (+19.7% upside). Prior stop was $42.60. Stop-loss: $42.60.
Concentration risk — Customer: Cencora, Cardinal Health, McKesson (76.0%); Concentration risk — Product: Qelbree (49.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9).
Supernus Pharmaceuticals, Inc. trades at a P/E of N/A (forward 10.2). TrendMatrix value score: 7.2/10. Verdict: Sell.
12 analysts cover SUPN with a consensus score of 4.2/5. Average price target: $63.
What does Supernus Pharmaceuticals, Inc. do?Supernus Pharmaceuticals is a commercial-stage CNS biopharmaceutical company with approved products for ADHD (Qelbree,...
Supernus Pharmaceuticals is a commercial-stage CNS biopharmaceutical company with approved products for ADHD (Qelbree, ~49% of 2025 net revenues), Parkinson’s disease (GOCOVRI, ~23%), postpartum depression (ZURZUVAE, ~8%), epilepsy, and other conditions. Products are sold through pharmaceutical wholesalers, with the top three distributors collectively accounting for over 76% of product revenue.